



Press Contact

Dr Barbara Domayne-Hayman
CEO, Stabilitech Ltd
bdh@stabilitech.com
+ 44 (0)7771 635450

FOR IMMEDIATE RELEASE

24th August 2010

Stabilitech Ltd

("Stabilitech" or "the Company")

STABILITECH IS AWARDED TECHNOLOGY STRATEGY BOARD GRANT

Stabilitech Ltd (London) announced today that it has been awarded a grant by the Technology Strategy Board as part of its competition on Detection and Identification of Infectious Agents: Fighting Infection through Detection.

Stabilitech will apply its broadly applicable stabilisation technology to stabilise a range of antibodies and antibody conjugates against infectious diseases, in order to enable storage and use of diagnostics at ambient and elevated temperatures. The grant is for a feasibility study of one year, towards which the Technology Strategy Board will provide up to £120,000.

Dr Barbara Domayne-Hayman, Stabilitech's CEO, said: "The grant will enable us to take our broadly applicable stabilisation technology into a new field for us, that of diagnostics. Our technology has exciting potential for the diagnostics field, since removing the need for refrigeration will greatly facilitate the use of point-of-care diagnostics, and will also enable their storage and use in developing countries. Further non-dilutive funding is much appreciated in these economically challenging times, and supplements our 2009 fund-raising.'

-ENDS-

Stabilitech Ltd

Dr Barbara Domayne-Hayman, CEO

+44 7771 635450

bdh@stabilitech.com

Notes for editors:

About Stabilitech

Stabilitech is a private company based in London, in the Imperial College Incubator. The company was founded by Dr Jeff Drew. Research on vaccines started in 2004 and the company has developed a novel proprietary technology which stabilises vaccines, biopharmaceuticals and other biological products.

Stabilitech's business model is to establish partnerships with major pharmaceutical and biotechnology companies, as well as global health organisations, to whom it will license the technology for commercialization.

In March 2009, Stabilitech raised £3.3 million, mainly from business angel investors.

Technology and Benefits:

Stabilitech's platform technology targets the following benefits:

- Protection of biopharmaceutical or vaccine efficacy where refrigeration standards are less rigorous – which include the increasing use of biopharmaceuticals in primary care settings and/or in patients' homes, as well as in developing countries.
- Stabilisation of unstable viruses and proteins, enabling a wider range of vaccines than is currently available.



Press Contact

Dr Barbara Domayne-Hayman
CEO, Stabilitech Ltd
bdh@stabilitech.com
+ 44 (0)7771 635450

- Greatly facilitated stockpiling, rapid deployment and logistics for thermo-stable vaccines in the field, including in harsh conditions with elevated ambient temperatures.
- A longer shelf life should be established, once a longer term of storage of bulk and final product is possible.
- Loss of entire vaccine batches due to temperature variations/maintenance during storage or distribution should become avoidable. Transportation and storage costs could be dramatically reduced.
- Competitive advantage via a differentiation platform for 'next generation' products, including the potential for extension of intellectual property protection, which is of interest both to major pharmaceutical companies and to bio-similars producers.

Stabilitech's approach involves the addition of carefully selected excipients at optimised concentrations and ratios, followed by freeze drying. Application of the technology fits into existing standard manufacturing procedures, thus involving minimal disruption. The excipients used have all been previously used in clinical settings, and all are relatively inexpensive and readily available.

About the Technology Strategy Board:

The Technology Strategy Board is a business-led executive non-departmental public body, established by the government. Its role is to promote and support research into, and development and exploitation of, technology and innovation for the benefit of UK business, in order to increase economic growth and improve the quality of life. It is sponsored by the Department for Business, Innovation and Skills (BIS). For further information please visit www.innovateuk.org.